Results 61 to 70 of about 1,334 (146)

Faricimab-svoa

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Bilateral occlusive retinal vasculitis secondary to intravitreal faricimab injection: a case report and review of literature

Eye and Vision
Background This article describes a rare occurrence of bilateral retinal occlusive vasculitis secondary to intravitreal faricimab injection. Case presentation A 72-year-old female with age-related macular degeneration presented with bilateral retinal ...
Yong Min Lee, Rajya Gurung, Jagjit Singh Gilhotra, Sumu Simon, Sudha Cugati   +4 more
doaj   +1 more source

Improving Clinic Capacity with Faricimab

EMJ Innovations
Clinic capacity constraints are an ever-increasing problem in ophthalmology. Multiple case studies demonstrate that faricimab frees up clinic capacity with extended treatment intervals in both treatment-naïve and treatment-experienced patients. In this symposium, three case studies from the UK and Spain demonstrated how fewer appointments per patient ...
David Wong, Romi Chhabra, Jorge Ruiz-Medrano, Robin Hamilton   +3 more
openaire   +1 more source

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

International Journal of Retina and Vitreous
Background Intravitreal faricimab, a bispecific antibody targeting both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), was recently introduced for the treatment of neovascular age-related macular degeneration (nAMD), diabetic ...
Gabriela Grimaldi, Giuseppe Cancian, Arianna Paris, Michele Clerici, Giulio Volpe, Moreno Menghini   +5 more
doaj   +1 more source

Faricimab for treating diabetic macular oedema

, 2021
To appraise the clinical and cost effectiveness of faricimab within its marketing authorisation for treating diabetic macular oedema.
Frampton, Geoff, Kalita, Neelam, Pickett, Karen, Maund, Emma, Takahashi, Marcia Tomie, Scott, David Alexander, Cooper, Keith   +6 more
openaire   +1 more source

Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept

Life
We investigated the factors associated with the success of switching to faricimab for type 1 macular neovascularization (MNV) refractory to intravitreal aflibercept (IVA).
Akira Machida, Akio Oishi, Junichiro Ikeda, Junko Kurihara, Ai Yoneda, Eiko Tsuiki, Yuki Hirata, Ryuya Murakami, Takashi Kitaoka   +8 more
doaj   +1 more source

Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis

Scientific Reports
We conducted a systematic review and meta-analysis to evaluate the visual, anatomical, and safety outcomes of the intravitreal faricimab, a novel vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2) bispecific agent, in neovascular age ...
Wei-Ting Yen, Chen-Shu Wu, Chang-Hao Yang, Yi-Hao Chen, Cho-Hao Lee, Cherng-Ru Hsu   +5 more
doaj   +1 more source

A CASE OF HYPERTENSIVE UVEITIS WITH INTRAVITREAL FARICIMAB

RETINAL Cases & Brief Reports
Purpose: The aim of this study was to report a novel case of hypertensive uveitis with intravitreal faricimab. Methods: This is a case report. A 69-year-old woman undergoing treatment of bilateral diabetic macular edema with intravitreal faricimab presented for routine review ...
Samantha Kitson, Andrew McAllister
openaire   +3 more sources

Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): seven-months results using artificial intelligence and OCTA

International Journal of Retina and Vitreous
Background To analyze the therapeutic response to faricimab 6 mg/0.05 ml in eyes with neovascular AMD (nAMD) with refractory intra- and/or subretinal fluid due to choroidal neovascularization (CNV), previously unresponsive to 4 mg monthly aflibercept and
Anna Heinke, Alexandra Warter, Ines D. Nagel, Akshay Agnihotri, Nehal Nailesh Mehta, Carlo Miguel B. Galang, Daniel N. Deussen, Dirk-Uwe G. Bartsch, Lingyun Cheng, Henry A. Ferreyra, William R. Freeman   +10 more
doaj   +1 more source

Short-term outcomes of faricimab and aflibercept 8 mg in diabetic macular edema

AJO International
Objective: To evaluate and compare the effectiveness and treatment burden of faricimab and aflibercept 8 mg in treatment-naive patients with diabetic macular edema (DME) using a pro re nata (PRN) protocol.
Carlo Maccauro, Yanny Jimenez Perez, Piergiorgio Neri, Ibraheem El Ghrably, Haytham I Salti, Francesco Pichi   +5 more
doaj   +1 more source